How AI is enabling pharmaceutical companies to make smarter decisions and stay ahead of the competition
Following an industry shift to focus on rare diseases and increased activity from smaller companies, the cost to bring a drug to market has now decreased to under $2bn for the first time in over five years. However, forecasted sales per approval are declining, raising concerns about long term sustainability.
In this dynamic environment, regulatory affairs and business development and licensing (BD&L) teams are feeling the pressure to make smarter, more accurate market decisions without increasing resources.
In this report, we examine the challenges facing both functions and present case studies on how artificial intelligence (AI) could be the solution needed to manage global complexity.
Fill out the form at the right to get your copy now!